相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis
S. Swindells et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Controlling latent TB tuberculosis infection in high-burden countries: A neglected strategy to end TB
Gavin J. Churchyard et al.
PLOS MEDICINE (2019)
Cytokine-Mediated Systemic Adverse Drug Reactions in a Drug-Drug Interaction Study of Dolutegravir With Once-Weekly Isoniazid and Rifapentine
Kristina M. Brooks et al.
CLINICAL INFECTIOUS DISEASES (2018)
Twelve-dose weekly rifapentine plus isoniazid for latent tuberculosis infection: A multicentre randomised controlled trial in Taiwan
Hsin-Yun Sun et al.
TUBERCULOSIS (2018)
Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium tuberculosis Infection
Andrey S. Borisov et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2018)
Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults
D. Menzies et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Latent tuberculosis infection: the final frontier of tuberculosis elimination in the USA
Philip A. LoBue et al.
LANCET INFECTIOUS DISEASES (2017)
The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis
Hannah Alsdurf et al.
LANCET INFECTIOUS DISEASES (2016)
Daily Rifapentine for Treatment of Pulmonary Tuberculosis A Randomized, Dose-Ranging Trial
Susan E. Dorman et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2015)
Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study
Timothy R. Sterling et al.
CLINICAL INFECTIOUS DISEASES (2015)
Latent Mycobacterium tuberculosis Infection
Haileyesus Getahun et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Treatment for Preventing Tuberculosis in Children and Adolescents A Randomized Clinical Trial of a 3-Month, 12-Dose Regimen of a Combination of Rifapentine and Isoniazid
M. Elsa Villarino et al.
JAMA PEDIATRICS (2015)
High-Dose Rifapentine with Moxifloxacin for Pulmonary Tuberculosis
Amina Jindani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Association of NAT2, GST and CYP2E1 polymorphisms and anti-tuberculosis drug-induced hepatotoxicity
Neha Singla et al.
TUBERCULOSIS (2014)
Rifapentine Pharmacokinetics and Tolerability in Children and Adults Treated Once Weekly With Rifapentine and Isoniazid for Latent Tuberculosis Infection
Marc Weiner et al.
JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY (2014)
NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: A randomized controlled trial for pharmacogenetics-based therapy
Junichi Azuma et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Human arylacetamide deacetylase is responsible for deacetylation of rifamycins: Rifampicin, rifabutin, and rifapentine
Akinori Nakajima et al.
BIOCHEMICAL PHARMACOLOGY (2011)
QuantiFERON®-TB Gold In-Tube for the detection of Mycobacterium tuberculosis infection in children with household tuberculosis contact
T. S. Kasambira et al.
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE (2011)
Risk factors of hepatitis during Anti-tuberculous treatment and implications of hepatitis virus load
Jann-Yuan Wang et al.
JOURNAL OF INFECTION (2011)
Three Months of Rifapentine and Isoniazid for Latent Tuberculosis Infection
Timothy R. Sterling et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Sex Differences in Pharmacokinetics and Pharmacodynamics
Offie P. Soldin et al.
CLINICAL PHARMACOKINETICS (2009)
The tuberculosis prodrug isoniazid bound to activating peroxidases
Clive Metcalfe et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy
M Weiner et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2004)
分享论文
